Press releases

Disruptive Pharma will attend Nordic Life Science Days in Stockholm, where Peter Åsberg and Martina Ferneman will meet with potential partners from the pharmaceutical and biotechnology industries. During the conference, we look forward to discussing Formulite®, oral drug development and formulation challenges where our technology can create...

Friday marked a special moment for Disruptive Pharma, as colleagues, Board members and guests gathered at Nasdaq Stockholm to celebrate the company's new chapter as a listed company. The opening bell ceremony was an opportunity to reflect on how far Disruptive Pharma and Formulite® have come – from many years of scientific research and...

Disruptive Pharma AB (publ), formerly Guard Therapeutics International AB (publ), (“Disruptive Pharma” or the “Company”) will ring the opening bell at Nasdaq Stockholm on 21 August 2026. On the same day, the Company’s shares will begin trading under the new ticker symbol DPHA, replacing GUARD. The bell-ringing ceremony marks the...

During summer 2026, Disruptive Pharma welcomed Johannes Schwarz, a Master's student at Uppsala University, to our labs in Uppsala through the SweDeliver Summer Internship programme. During his internship, Johannes explored how different formulations influence the tableting process and the properties of the final tablets. The project provided...

27 July 2026 – Guard Therapeutics International AB (publ) (to be renamed Disruptive Pharma AB (publ)) ("Guard Therapeutics" or the "Company") today announces that the reverse takeover (RTO) of Disruptive Pharma Holding AB (publ) ("Disruptive Pharma"), pursuant to the agreement entered into and announced on 10 June 2026, has been completed...